» Articles » PMID: 36792751

A Timeline of Tumour-associated Macrophage Biology

Overview
Journal Nat Rev Cancer
Specialty Oncology
Date 2023 Feb 15
PMID 36792751
Authors
Affiliations
Soon will be listed here.
Abstract

Tumour progression is modulated by the local microenvironment. This environment is populated by many immune cells, of which macrophages are among the most abundant. Clinical correlative data and a plethora of preclinical studies in mouse models of cancers have shown that tumour-associated macrophages (TAMs) play a cancer-promoting role. Within the primary tumour, TAMs promote tumour cell invasion and intravasation and tumour stem cell viability and induce angiogenesis. At the metastatic site, metastasis-associated macrophages promote extravasation, tumour cell survival and persistent growth, as well as maintain tumour cell dormancy in some contexts. In both the primary and metastatic sites, TAMs are suppressive to the activities of cytotoxic T and natural killer cells that have the potential to eradicate tumours. Such activities suggest that TAMs will be a major target for therapeutic intervention. In this Perspective article, we chronologically explore the evolution of our understanding of TAM biology put into the context of major enabling advances in macrophage biology.

Citing Articles

Targeting both death and paracaspase domains of MALT1 with antisense oligonucleotides overcomes resistance to immune-checkpoint inhibitors.

Tao Y, Tian C, Qi S, Jia Z, Xu Z, Meng J Nat Cancer. 2025; .

PMID: 40075237 DOI: 10.1038/s43018-025-00930-5.


Biomimetic Self-Oxygenated Immunoliposome for Cancer-Targeted Photodynamic Immunotherapy.

Tang Y, Tang T, Li Y, Wu J, Liu X, Xiang D Int J Nanomedicine. 2025; 20:2743-2759.

PMID: 40066322 PMC: 11892501. DOI: 10.2147/IJN.S508696.


Tebentafusp, a T cell engager, promotes macrophage reprogramming and in combination with IL-2 overcomes macrophage immunosuppression in cancer.

Guc E, Treveil A, Leach E, Broomfield A, Camera A, Clubley J Nat Commun. 2025; 16(1):2374.

PMID: 40064880 PMC: 11893752. DOI: 10.1038/s41467-025-57470-w.


Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets.

Guan F, Wang R, Yi Z, Luo P, Liu W, Xie Y Signal Transduct Target Ther. 2025; 10(1):93.

PMID: 40055311 PMC: 11889221. DOI: 10.1038/s41392-025-02124-y.


An adoptive cell therapy with TREM2-overexpressing macrophages mitigates the transition from acute kidney injury to chronic kidney disease.

Zhang Y, Liu Y, Luo S, Liang H, Guo C, Du Y Clin Transl Med. 2025; 15(3):e70252.

PMID: 40000418 PMC: 11859120. DOI: 10.1002/ctm2.70252.


References
1.
Stehelin D, Varmus H, Bishop J, Vogt P . DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 1976; 260(5547):170-3. DOI: 10.1038/260170a0. View

2.
Lipsick J . A History of Cancer Research: Tumor Suppressor Genes. Cold Spring Harb Perspect Biol. 2020; 12(2). PMC: 6996451. DOI: 10.1101/cshperspect.a035907. View

3.
Gerstung M, Jolly C, Leshchiner I, Dentro S, Gonzalez S, Rosebrock D . The evolutionary history of 2,658 cancers. Nature. 2020; 578(7793):122-128. PMC: 7054212. DOI: 10.1038/s41586-019-1907-7. View

4.
Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

5.
Bissell M, Hines W . Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011; 17(3):320-9. PMC: 3569482. DOI: 10.1038/nm.2328. View